Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$4.65 USD

4.65
72,293

-0.06 (-1.27%)

Updated Oct 18, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ACOR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Acorda Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 84 139 446 307 159
Receivables 20 22 23 81 52
Notes Receivable 0 0 0 0 0
Inventories 29 25 29 38 43
Other Current Assets 88 15 30 15 19
Total Current Assets 221 201 528 442 273
Net Property & Equipment 7 143 61 37 34
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 2 7
Intangibles 367 402 711 717 1,023
Deposits & Other Assets 19 30 0 1 6
Total Assets 633 800 1,300 1,198 1,342
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 69 1 1 7 6
Accounts Payable 12 26 49 27 27
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 38 39 77 100 105
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 10 13 14 9 10
Total Current Liabilities 137 86 140 144 148
Mortgages 0 0 0 0 0
Deferred Taxes/Income 19 10 7 46 125
Convertible Debt 138 193 319 309 299
Long-Term Debt 29 26 24 26 25
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 55 152 197 154 81
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 395 489 688 678 678
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,008 979 1,005 969 921
Retained Earnings -766 -667 -394 -455 -244
Other Equity -3 -1 3 7 -13
Treasury Stock 1 1 2 0 0
Total Shareholder's Equity 238 311 612 520 664
Total Liabilities & Shareholder's Equity 633 800 1,300 1,198 1,342
Total Common Equity 238 311 612 520 664
Shares Outstanding 8.00 8.00 7.90 7.70 7.60
Book Value Per Share 29.75 38.85 77.47 67.53 87.40

Fiscal Year End for Acorda Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Assets          
Cash & Equivalents NA 59 130 84 76
Receivables NA 14 17 20 13
Notes Receivable NA 0 0 0 0
Inventories NA 25 27 29 30
Other Current Assets NA 15 15 88 32
Total Current Assets NA 113 190 221 152
Net Property & Equipment NA 6 6 7 139
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 351 359 367 375
Deposits & Other Assets NA 12 19 19 25
Total Assets NA 492 584 633 710
Liabilities & Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Notes Payable NA 0 69 69 68
Accounts Payable NA 17 9 12 10
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 29 38 38 41
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 11 11 10 11
Total Current Liabilities NA 68 133 137 139
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 15 16 19 23
Convertible Debt NA 144 141 138 135
Long-Term Debt NA 28 28 29 27
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 51 55 55
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 301 378 395 397
Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,016 1,009 1,008 1,000
Retained Earnings NA -823 -800 -766 -683
Other Equity NA -2 -2 -3 -2
Treasury Stock NA 1 1 1 1
Total Shareholder's Equity NA 190 206 238 314
Total Liabilities & Shareholder's Equity NA 492 584 633 710
Total Common Equity 0 190 206 238 314
Shares Outstanding 11.10 9.40 9.40 8.00 8.00
Book Value Per Share 0.00 20.26 21.94 29.75 39.19